Sentiment Behind FDA Approval of Alexza's (ALXA) Adusave Improves; Shares Higher Today
Tweet
Share
E-mailGet Alerts ALXA Hot Sheet
Join SI Premium – FREE
Alexza Pharmaceuticals (Nasdaq: ALXA) is higher on the session amid positive sentiment behind its Adasuve receiving FDA approval tomorrow.
Last week, Alexza reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Adusave, though the FDA has been less forgiving (two CRLs on Adusave and counting).
A Seeking Alpha article out today interviews Roth Capital's Scott Henry, whom is the head of healthcare research at the firm.
In short, Henry expects the FDA to issue a PDUFA date for Adusave. He also expects U.S. sales of $13 million, $74 million, $134 million, and $207 million for years 2013 to 2016.
Shares are up 12 percent today on heavy volume.
Last week, Alexza reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Adusave, though the FDA has been less forgiving (two CRLs on Adusave and counting).
A Seeking Alpha article out today interviews Roth Capital's Scott Henry, whom is the head of healthcare research at the firm.
In short, Henry expects the FDA to issue a PDUFA date for Adusave. He also expects U.S. sales of $13 million, $74 million, $134 million, and $207 million for years 2013 to 2016.
Shares are up 12 percent today on heavy volume.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inspire Medical (INSP), ResMed (RMD) on Watch Following Report on Sleep Apnea
- YS Biopharma (YS) Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
- PowerSchool Holdings, Inc. (PWSC) Mentioned Cautiously at Spruce Point
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
